Clinical Trials Logo

Clinical Trial Summary

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions


Clinical Trial Description

Subjects enrolled in Cohort 1 will have a region of healthy buttock skin as a non-facial target area to receive two (2) injectable doses of KB301 (low or high). Cohort 1a will also present two regions of healthy buttock skin as a non-facial target area to receive two (2) injectable doses of KB301 (low or high) as well as a placebo injection. The objective of this cohort is to evaluate COL3A1 transgene expression (as measured by qRT-PCR of skin biopsies) and determine the optimal dose. Subjects enrolled in Cohort 2 will present with bilaterally symmetrical regions of moderate to severe fine lines and skin roughness as the target areas; these areas will be randomly assigned to receive either KB301 or a placebo to determine the extent of skin improvement in the KB301 arm. Throughout the study subjects will complete questionnaires, have images captured of the target areas, undergo physical examinations, and have safety labs monitored. Cohort 2 subjects may enroll in Cohort 2 extension, if they have not reverted back to baseline on the KB301 treated target area of the cheek. If subjects received KB301 to both cheek areas they will not be eligible for additional treatment and will be followed for durability. Subjects who received KB301 treatment to one cheek area, who have not reverted to baseline on the KB301 treated target area will be treated with KB301 on the cheek which previously received placebo. Subjects will be followed for durability, captured through investigator assessments, and questionnaires, while continuing to monitor safety. Cohort 3 will be open label. Subjects will present with mild to moderate lateral canthal lines. The cohort will be split into two (3) subsets, Cohort 3a, Cohort 3b and Cohort 3c. Subjects in Cohort 3a and Cohort 3c will receive microinjections of KB301 and subjects in Cohort 3b will receive microneedling prior to topical application of KB301. Throughout the study, subjects will complete questionnaires, have images captured of the target areas, undergo physical examinations, and have assessment of improvement completed by the investigator. At Visit 5 the subject may begin retreatment with KB301 once weekly for three weeks and then will be followed for an additional 3 months, at the discretion of the investigator. Cohort 4 will be open label. Subjects will present with dynamic décolleté wrinkles and/or pigmentation. Subjects in Cohort 4 will receive microinjections of KB301 to the décolleté area. Throughout the study, subjects will complete questionnaires, have images captured of the target areas, undergo physical examinations, and have assessment of improvement completed by the investigator. At Visit 5 the subject may begin retreatment with KB301 once weekly for three weeks and then will be followed for an additional 3 months, at the discretion of the investigator. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04540900
Study type Interventional
Source Krystal Biotech, Inc.
Contact Brittani Agostini
Phone 412-586-5830
Email bagostini@krystalbio.com
Status Recruiting
Phase Phase 1
Start date October 7, 2020
Completion date May 31, 2029

See also
  Status Clinical Trial Phase
Completed NCT05098912 - Comparing Polydioxanone Thread Embedding Acupuncture and Manual Acupuncture for Nasolabial Fold Reduction N/A
Completed NCT05271136 - A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum N/A
Completed NCT05096247 - Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device N/A
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT04128046 - The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation N/A
Active, not recruiting NCT04727099 - Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™ N/A
Active, not recruiting NCT06140628 - A 28-day Clinical Study on Facial Skin Rejuvenation N/A
Not yet recruiting NCT05524779 - BTL-785F Device for Non-invasive Reduction of Wrinkles and Overall Facial Improvement N/A
Completed NCT05514782 - A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum N/A
Completed NCT06123572 - A Clinical Study to Assess the Safety and Effectiveness of Anti-Ageing and Skin Brightening Gel N/A
Completed NCT04911374 - An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream N/A
Recruiting NCT04989361 - Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles. N/A
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Recruiting NCT06074276 - The Effects of Almond on Facial Skin Collagen and Wrinkles N/A
Completed NCT06366503 - Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation N/A
Active, not recruiting NCT06219278 - A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles N/A
Active, not recruiting NCT06192550 - Functional Usability and Feasibility Testing of the Profound Matrix™ System N/A
Completed NCT04650620 - Study to Evaluate the Performance and Safety of the Medical Device Plenhyage® N/A
Completed NCT03729700 - The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome N/A
Completed NCT05102617 - Post Market Usability Evaluation Of The PicoSure Pro Device N/A